Compounded semaglutide is not a brand-name Ozempic or Wegovy generic with a different label. Compounding is a pharmacy or outsourcing-facility activity that may occur under specific provisions of U.S. law when their conditions are met. Compounded drugs are not approved by FDA, which means FDA does not independently review each preparation for safety, effectiveness or quality before marketing.
FDA declared the U.S. shortage of semaglutide injection products resolved on February 21, 2025. In April 2026, the agency reiterated limits on routinely producing products that are essentially copies of available approved drugs. The rules distinguish patient-specific compounding under section 503A from qualifying outsourcing-facility activities under section 503B, and legal conclusions depend on the actual product and factual circumstances.
This page explains why a low-priced “compounded Ozempic” advertisement cannot be evaluated as an approved substitute, what warning signs FDA has documented, and what questions a buyer should ask. For current approved products use the FDA product directory; for the overall lawful purchase workflow use the buying guide.
A compounding pharmacy may hold a state license and still prepare a drug that has not been reviewed under an FDA marketing application. Conversely, a licensed facility does not receive a general exemption to mass-produce copycat products simply because it has a license. Evaluate the compounder’s status, the legal compounding basis and the individual prescription separately.
FDA-approved manufactured presentations have evaluated labeling and standardized product identifiers. Compounded preparations can vary in concentration, container, ingredients and instructions, increasing the importance of precise professional oversight.
This table is a buyer-oriented summary of FDA’s April 1, 2026 policy explanation, not a determination that an individual proposed prescription qualifies under federal or state law.
A state license, clean-looking label or advertised price does not resolve whether copying restrictions apply. The generic-status guide explains why compounded does not mean FDA-approved generic.
| Route or claim | What the buyer should understand | Evidence to request |
|---|---|---|
| FDA-approved Ozempic or Wegovy | Approved brand and form, prescription-only | Exact FDA-labeled product and authorized dispenser |
| 503A patient-specific compounding | Must meet statutory conditions, including individual prescription and limits on essentially copies | Qualified prescriber and compounding pharmacy identity |
| 503B outsourcing-facility product | Different statutory conditions and restrictions on copies and bulk substances | Registered facility and precise product basis |
| “FDA-approved compounded semaglutide” | Misleading characterization: compounded drug itself is not FDA-approved | Do not treat the claim as approval evidence |
| Semaglutide sodium or acetate | FDA has identified unresolved safety and lawful-use concerns regarding these salt forms | Clarify actual active ingredient with clinician/pharmacist |
| “Generic Ozempic compounded injection” | Compounding is not ANDA-approved generic substitution | Check Drugs@FDA/Orange Book for genuine generic status |
Certain compounding allowances are tied to the FDA drug shortage list, and the end of shortage status changes how pharmacies and outsourcing facilities assess copies. FDA’s transition periods for shortage-based enforcement discretion ended in 2025. It is therefore misleading to sell a routine mass-market copy based only on an old shortage notice.
A patient-specific exception cannot be inferred from advertising language alone. Actual legal permissibility requires evaluating the preparation and applicable requirements, not simply the patient’s desire for a lower price.
FDA’s April 2026 clarification describes section 503A compounding for an individual patient based on a prescription and the prohibition on compounding regularly or in inordinate amounts products that are essentially copies of commercially available drugs. Patient-specific clinical differences may matter under the statutory and guidance framework.
A buyer should ask what the clinical rationale is for this particular preparation and who will verify it. Neither the website nor an affiliate program can declare that routine compounded semaglutide qualifies for every patient.
Section 503B governs qualifying registered outsourcing facilities, which operate under a different set of conditions from patient-specific 503A pharmacies. Registration as an outsourcing facility does not mean its individual products have FDA premarket approval, nor does it create an unconditional right to copy a commercially available FDA-approved medicine.
On April 30, 2026 FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list after reviewing claimed clinical need. As announced, this was a proposal open to comment, not itself a final rule or a factual finding that all compounding in every setting is unlawful. Readers must verify any later final action and the specific statutory basis for a proposed product.
FDA has warned that semaglutide sodium and semaglutide acetate are different active ingredients from the semaglutide base in approved products. FDA has not identified a lawful basis under the applicable compounding conditions for use of these salt forms and lacks evidence that their properties are equivalent to the approved ingredient.
Do not accept a marketing claim of identical effectiveness or dosing because the word “semaglutide” appears in the ingredient line. Ask the treating clinician and pharmacist to identify the precise ingredient and any documented risks.
FDA documented serious dosing errors, including hospitalizations, associated with some compounded semaglutide injections dispensed in variable-concentration vials or syringes. Confusion between milligrams, milliliters and insulin-syringe “units” is especially risky.
Do not attempt a self-directed conversion from a branded pen to a compounded vial. If a legitimately prescribed compounded preparation is involved, its specific instructions require direct professional explanation and confirmation.
Be cautious about “FDA-approved compound,” “the same as Ozempic,” “no prescription necessary,” “generic Wegovy in bulk,” and “everyone qualifies for the same low monthly price.” These claims ignore either product approval, prescribing requirements, legal copy limitations or patient-specific circumstances.
The pharmacy verification checklist can help assess the dispenser; the counterfeit guide addresses suspected falsification rather than lawful compounding.
Compounding is not the same as buying a fully manufactured brand marketed in another country. Foreign brand approval does not grant U.S. approval, and importing foreign ingredients for legitimate U.S. pharmaceutical manufacture differs from shipping an unapproved drug directly to a consumer.
See imported semaglutide rules for the separate cross-border question. Neither category should be marketed as an interchangeable FDA-approved Ozempic or Wegovy substitute.
First identify the FDA-approved medicine, form and indication relevant to the actual prescription; then check the licensed dispensing channel and financial terms. If a clinician proposes a compounded preparation for a specific need, discuss why an approved product does not meet that need, the preparation’s source and its risks.
For branded access use Ozempic prescription and pharmacy routes or Wegovy prescription and pharmacy routes. The purpose is informed verification, not promotion of mass-marketed unapproved copies.
Approved semaglutide labeling includes a boxed warning concerning thyroid C-cell tumors and contraindications including personal or family history of medullary thyroid carcinoma or MEN2. Other serious risks are product-specific and must be considered by the prescribing clinician.
A compounded product cannot borrow approved labeling or a brand’s clinical trials as proof that its own formulation was evaluated by FDA. The exact prescriber and pharmacist must explain the actual preparation and safety information.
A website may describe itself as "503A compliant" without identifying the licensed pharmacy, or imply that a general personal preference for a lower price is enough to establish a legally significant difference from an available approved drug. Ask who determined the documented clinical need, which specific final formulation will be made, and which federal and state requirements apply. A routine marketed copy is a different regulatory issue from genuinely individualized preparation.
A second claim to check is that a facility is "FDA registered" and the preparation is therefore "FDA approved." Registration or inspection can identify an establishment without FDA approving each compounded drug. If a marketplace does not disclose the actual finished preparation and responsible dispenser, do not assume its products have the same proven quality, safety or effectiveness as approved brands.
As of the October 19, 2026 review, the key federal milestones include FDA’s February 21, 2025 resolution of the injection shortage, its April 1, 2026 explanation of section 503A/503B copy restrictions and the April 30, 2026 proposed exclusion of these GLP-1 ingredients from the 503B bulks list. These statements have different legal effects and should not be collapsed into one all-purpose "ban."
Independent consumer guidance cannot validate an individual pharmacy’s legal interpretation. An offer should identify the pharmacy or outsourcing facility, the actual ingredients and concentration, the patient-specific justification where required, the responsible prescriber and the basis for compliance. Compensation from outbound links, if disclosed, never verifies legality or therapeutic equivalence.
No. Compounded medicines do not undergo FDA premarket approval for safety, efficacy and quality.
No blanket statement is accurate. Limited patient-specific compounding can be lawful if all relevant federal and state statutory conditions are met.
Certain compounding permissions depend on shortage status. FDA announced the injection shortage was resolved in February 2025, and the related transition periods ended in 2025.
No. FDA generic approval uses a drug application pathway distinct from pharmacy compounding.
FDA has identified these as salt forms different from the base ingredient in approved medicines and has raised legal and safety concerns.
No. Formulations, concentration and administration instructions can differ, and FDA has reported serious dosing errors with some compounded injections.
No. Facility status does not convert an individual compounded product into an FDA-approved medicine.
Such a promise is a warning sign. Lawful compounding can require a valid patient-specific prescription and other conditions.
Ask about the individualized need, facility, actual active ingredient, concentration, administration instructions, safety monitoring and whether an FDA-approved product could meet the need.